<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView%20&amp;noscript=1">

Extensive Stage Small Cell Lung Cancer Study

This study is testing how safe and effective two new compounds are for the identification and treatment of patients with extensive stage small cell lung cancer (ES-SCLC).

ES-SCLC is a type of lung cancer that has spread into other parts of the body, and life expectancy is low with current available treatments. The approach of using two compounds, one for diagnosis, one for therapy is called ‘theranostics’, and it is designed to find and act on cancer cells with greater precision. Participation in this research study is voluntary, and you may withdraw from the study at any time.

Eligibility
  • 18 years or older
  • Confirmed diagnosis of ES-SCLC
  • Additional criteria discussed at a later time point with a physician
Location
  • WA, VIC, QLD, NSW
Duration
  • Your time on the study may last several months.
Read more
SCLC CIRCLE

If you take part in the research study, there will be:

Reimbursement of costs

For out-of-pocket expenses, such as travel and parking.

Free study-related medical care

Access a potentially new, highly targeted form of cancer therapy.

Expert medical monitoring

Receive ongoing monitoring and support from specialist healthcare professionals.

Convenience

There are no overnight stays, and all study visits are outpatient only.

Contribution to medical research

Help potentially advance knowledge and treatment outcomes in cancer research.

Register your interest now

or scroll down to read our FAQs

Study Guide

01

How long will the study take?

-

If you are deemed eligible for the study, your participation is in conjunction with standard of care treatment. 

Typical standard of care involves:

  1. Induction Phase immunotherapy (atezolizumab) and chemotherapy every three weeks for 3 months.
  2. Maintenance Phase:  atezolizumab every three weeks for between 6 and 24 months 

Study Treatment involves:
  • A screening phase which coincides with standard of care induction therapy for 3 months. During the screening period, you will receive a scan with a diagnostic product to confirm the presence of a specific target protein found in your cancer cells.
  • If the scan is positive for the target, and you are eligible for the maintenance phase of immunotherapy, you will enter the treatment phase which will consist of study drug being administered approximately every 6 weeks
  • After receiving the final treatment of study drug, the long-term follow-up will begin
  • Participation in this research study is voluntary, and you may withdraw from the study at any time.

02

What is the purpose of this study?

+

This study is testing how safe and effective two new compounds are for the identification and treatment of patients with extensive stage small cell lung cancer (ES-SCLC).

The two  products are Gallium-SSO120, a diagnostic imaging product, and Lutetium-SSO110, the radiopharmaceutical treatment you will receive..

The imaging product is expected to detect the target protein SST2, which is found in small cell lung cancer cells. The radiopharmaceutical treatment is expected to bind to this target and deliver radiation to kill the cancer cells.

03

What is extensive stage small cell lung cancer?

+

Extensive stage small cell lung cancer (ES-SCLC) is the most aggressive type of lung cancer. ES-SCLC typically originates in the bronchi, breathing tubes that connect the airway to the lungs, before spreading into (metastasising) lymph nodes, organs, and other parts of the body via the bloodstream. 

For more information about ES-SCLC, and where to find support, please visit the Cancer Council Australia website.

04

Why is this study important?

+

Small cell lung cancer (SCLC) accounts for 10-15% of all newly diagnosed lung cancers, and most SCLC patients will receive a diagnosis only after the cancer has spread into other parts of the body.

As such, there is a need for targeted therapy that finds and acts on cancer cells with greater precision. This study presents one such opportunity to improve the treatment outcomes for people with ES-SCLC. 

05

Who is sponsoring this study?

+

This study is being sponsored by Ariceum Therapeutics (Ariceum), a radiopharmaceutical company headquartered in Berlin and active across Europe, Australia, and North America.

Launched in 2021, Ariceum focuses on the diagnosis and precision treatment of neuroendocrine cancers, childhood cancer, and certain aggressive tumours, which currently have few treatment options and poor prognosis.

In fact, the name Ariceum is an anagram of ‘Marie Curie’, whose discovery of radium and polonium has played a pivotal role in finding cancer treatments. 

06

Where is my nearest study site?

+

Here is a list of all the sites who are currently recruiting for this study:

  • [insert list of sites]



07

What if I have other questions about the study?

+

We're here for you! Click or tap the 'Contact us' button below to send an email to our friendly Patient Experience team:

Contact us

Help make medical research breaktrhoughs happen.